Novavax (NVAX) Misses Q1 EPS by 13c; offers outlook

Novavax (NASDAQ: NVAX) reported Q1 EPS of ($1.05), $0.13 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $93.85 million versus the consensus estimate of $141.16 million.

GUIDANCE:

Novavax sees FY2024 revenue of $800 million to $1 billion, versus the consensus of $845.5 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Citi upgrades Bath & Body Works to Buy with $25 price target
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24